Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in advanced Merkel cell carcinoma
NCT03783078Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of pembrolizumab in Merkel cell carcinoma (MCC), sponsored by Merck & Co.. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03783078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783078.